RMD ResMed Inc.

ResMed’s New QuietAir Diffuser Vent for CPAP Masks Reduces Noise by 89 Percent

SAN DIEGO--(BUSINESS WIRE)--

ResMed (NYSE: RMD) (ASX: RMD) today introduced the QuietAir diffuser vent elbow, for its latest continuous positive airway pressure (CPAP) full face masks: AirFit F20 with silicone cushion and AirTouch F20 with memory foam cushion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180510005362/en/

ResMed QuietAir diffuser vent elbow (Photo: Business Wire)

ResMed QuietAir diffuser vent elbow (Photo: Business Wire)

QuietAir reduces noise by 89 percent and produces a 70 percent gentler exhaled airflow, compared to ResMed’s previous design, allowing for a quiet, uninterrupted night of sleep and mitigating two barriers to therapy compliance: noise and bed partner comfort.

“With this technology, our full face masks’ noise levels are well below ambient noise in the bedroom,” said ResMed CEO Mick Farrell. “We are providing patients and their bed partners with the peace and quiet they deserve for better sleep.”

QuietAir is the latest innovation to ResMed’s line of AirFit and AirTouch products:

  • AirTouch F20 with UltraSoft memory foam launched in May 2017, creating a personalized fit with a uniquely soft and breathable seal, and fitting 98 percent of patients.
  • AirFit F20 and AirFit N20 nasal masks launched in November 2016 to enhance facial comfort and fit, fitting 97 and 99 percent of patients, respectively, regardless of facial structure, gender or age.

All three masks complement ResMed’s suite of cloud-connected PAP devices: Air10 bedside machines and AirMini, the world’s smallest PAP device. Remote and self-monitoring, enabled by cloud connectivity, is proven to help improve patients adherence and clinicians’ business efficiencies.

QuietAir diffuser vents for AirFit F20 and AirTouch F20 masks are now available in the Americas, EMEA and Asia-Pacific. For more information, contact your ResMed sales representative.

About ResMed

ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health company with more than 5 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries. ResMed.com

EN
10/05/2018

Underlying

RMDResMed Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ResMed Inc.

 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Expands U.S. Operations with New Distribution Center in Greenwo...

Resmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana Center to Create Local Jobs and Strengthen U.S. Healthcare Supply Resilience SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, is opening a new distribution center in Greenwood, Indiana. Scheduled to begin operations in 2027, the center will expand Resmed’s U.S. presence and strengthen the company's distribution capacity to better serve patients and providers across North America. The...

February 24, 2026 1 EN
Free Trial
RMD RESMED INC.

ResMed Inc: 2 directors

Two Directors at ResMed Inc sold 2,050 shares at between 251.310USD and 260.000USD. The significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...

02/09/26 February 9, 2026 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 20...

Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026 Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%Income from operations increased 18%; non-GAAP income from operations up 19%Diluted earnings per share of $2.68; non-GAAP diluted earnings per share of $2.81Operating cash flow of $340 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at  SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today an...

January 29, 2026 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 20...

Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, January 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:•Location:•Date:Thursday, January 29, 2026•Time:1:30 p.m. PST /...

January 8, 2026 1 EN
 PRESS RELEASE
Free
RMD RESMED INC.

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthca...

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, beginning at approximately 10:30 a.m. (Pacific Standard Time) in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting . The audio-only webcast replay...

December 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch